Highlights Genmab A/S

Equities

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:49 2024-05-08 EDT			5-day change	1st Jan Change
2,003 ^DKK	-0.45%		+1.91%	-7.05%

05-03	GENMAB : A good start to 2024; guidance unchanged
05-03	Genmab Posts Q1 Net Profit Surge; Revenue Jumps	MT

GENMAB : A good start to 2024; guidance unchanged	05-03
Genmab Posts Q1 Net Profit Surge; Revenue Jumps	05-02	MT
Genmab Reports Higher Interim Q1 Results; Maintains 2024 Guidance	05-02	MT
Genmab A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer	04-30	MT
Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer	04-29	CI
Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug	04-16	MT
Health Care Slips on Risk Bias -- Health Care Roundup	04-11	DJ
Health Care Flat on Rotation to Rate-Sensitive Sectors -- Health Care Roundup	04-03	DJ
News Highlights : Top Company News of the Day - Wednesday at 11 AM ET	04-03	DJ
Global markets live: Swiss Re, Intel, Walt Disney, Paramount, Microsoft...	04-03
News Highlights : Top Company News of the Day - Wednesday at 9 AM ET	04-03	DJ
Correction to Genmab Article	04-03	DJ
Genmab: acquisition of ProfoundBio greeted without emotion	04-03	CF
News Highlights : Top Company News of the Day - Wednesday at 7 AM ET	04-03	DJ
Genmab A/S Re-Affirms Revenue Guidance for the Year 2024	04-03	CI
News Highlights : Top Company News of the Day - Wednesday at 5 AM ET	04-03	DJ
Genmab Strengthens Oncology Portfolio With $1.8 Billion Acquisition of ProfoundBio	04-03	DJ
Genmab Looks to Expand Clinical Pipeline with $1.8 Billion Purchase of Cancer-focused ProfoundBio	04-03	MT
Denmark's Genmab to acquire ProfoundBio for $1.8 billion	04-03	RE

No results for this search

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 01:08 pm